Lista de obras -

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

artículo científico publicado en 2009

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b

artículo científico publicado en 2015

Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making

artículo científico publicado en 2015

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

artículo científico publicado en 2018

Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study

article

Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop

artículo científico publicado en 2014

Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary

artículo científico publicado en 2015

Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci

artículo científico publicado en 2011

Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group

artículo científico publicado en 2017

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial

artículo científico publicado en 2016

Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

artículo científico publicado en 2014

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

artículo científico publicado en 2011

No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.

artículo científico publicado en 2015

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b

artículo científico publicado en 2015

Smart-Dust-Nanorice for Enhancement of Endogenous Raman Signal, Contrast in Photoacoustic Imaging, and T2-Shortening in Magnetic Resonance Imaging

scientific article published on 10 April 2018

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

artículo científico publicado en 2017

Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures

artículo científico publicado en 2015

Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting

artículo científico publicado en 2017

Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies

artículo científico publicado en 2012

Vitamin D as an early predictor of multiple sclerosis activity and progression

artículo científico publicado en 2014

Lista de obras de

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b

Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials

Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study

Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop

Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: Report of the OMERACT 2014 RA Flare Group Plenary

Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci

Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial

Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b

Smart-Dust-Nanorice for Enhancement of Endogenous Raman Signal, Contrast in Photoacoustic Imaging, and T2-Shortening in Magnetic Resonance Imaging

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures

Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting

Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies

Vitamin D as an early predictor of multiple sclerosis activity and progression